HC Wainwright set a $4.00 price objective on Ampliphi Biosciences (NYSEAMERICAN:APHB) in a research report sent to investors on Friday. The firm currently has a buy rating on the biotechnology company’s stock.
“Valuation and risks to price target achievement. We reiterate our Buy rating at the price target of $3.50. We project the following in our clinical NPV model for S. aureus: (1) projected launch in 2021 for bacteremia with a 15% chance of success and $300 million in peak sales; and (2) projected launch in 2022 for prosthetic joint infections with a 10% chance of success and $200 million in peak sales.”,” the firm’s analyst commented.
Shares of Ampliphi Biosciences stock remained flat at $$0.30 during trading on Friday. 261,636 shares of the stock traded hands, compared to its average volume of 426,714. Ampliphi Biosciences has a 1-year low of $0.25 and a 1-year high of $2.05.
Ampliphi Biosciences Company Profile
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections.
Read More: What is Liquidity?
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.